Ask Our Experts: Navigating the Complexities of Bioconjugation Development and Manufacturing


As bioconjugate therapeutics continue to evolve beyond conventional antibody-drug conjugates (ADCs), developers are exploring increasingly diverse combinations of antibodies, linkers, and functional payloads. These advances are creating new opportunities for targeted therapeutics while introducing additional considerations for process development and manufacturing.
Supporting this growing diversity requires expertise across conjugation technologies, payload characteristics, process optimization, and contamination control. Each component plays an important role in establishing manufacturing processes that can accommodate different molecular properties and development requirements.
During two recent webinars exploring Samsung Biologics' comprehensive bioconjugation services and risk-based contamination control strategies, industry participants raised practical questions about these challenges. In this Q&A article, our two experts will address those questions, sharing insights on technical and operational considerations for ADC development and manufacturing.
Q1. What advantages can enzymatic conjugation offer over conventional conjugation methods?
Selecting the appropriate conjugation technology is a critical step in bioconjugate development, as the method can influence product homogeneity, stability, and overall quality. While conventional cysteine-based conjugation methods are widely used, enzyme-mediated conjugation can offer advantages in controlling drug-to-antibody ratio (DAR) and improving product homogeneity.
One key benefit of enzyme-mediated conjugation is its ability to preserve the antibody's native structure. Unlike certain cysteine-based approaches that involve disrupting native disulfide bonds, enzyme-mediated methods can enable conjugation without altering these structural features. This can contribute to improved ADC stability and more consistent product characteristics.
Greater control over DAR distribution is another important consideration, particularly for ADCs. ADC populations with lower DAR values may exhibit reduced efficacy, while those with higher DAR values can present increased toxicity risks. Achieving a more homogeneous DAR profile can therefore help support a balance between efficacy and safety.
However, no single conjugation approach is optimal for every molecule. Factors such as reaction efficiency, conjugation site specificity, payload characteristics, and desired product attributes must be considered when selecting a suitable method.
Samsung Biologics supports process development and manufacturing across a range of conjugation technologies, including enzyme-mediated approaches, enabling clients to select methods suited to their ADC programs.
Q2. How does experience with different payloads and DAR values support ADC process development?
The increasing diversity of bioconjugate modalities introduces a wide range of molecular characteristics and process requirements. Different payloads and linker combinations can influence conjugation efficiency, product stability, and manufacturing conditions. For ADC development in particular, experience handling highly potent payloads and achieving different DAR targets is essential to establishing suitable conjugation processes.
Samsung Biologics has experience handling and conjugating a variety of payloads, including monomethyl auristatin E (MMAE)*, exatecan*, pyrrolobenzodiazepine* (PBD), and oligonucleotides*. Its process development experience also encompasses target DAR values ranging from 1 to 8. This experience provides a foundation for evaluating different payload-linker combinations and developing conjugation processes tailored to specific product requirements.
* Monomethyl auristatin E (MMAE) is a potent synthetic antimitotic agent derived from the marine-derived peptide dolastatin 10.
* Exatecan (DX-8951) is a potent, water-soluble structural analog of camptothecin and a DNA topoisomerase I inhibitor.
* Pyrrolobenzodiazepine (PBD) is a highly potent ADC payload that kills cancer cells by damaging their DNA.
* Oligonucleotide conjugation is the process of chemically linking short DNA or RNA molecules to other molecules, such as antibodies, peptides, or lipids, to improve targeted drug delivery and therapeutic effectiveness.
As bioconjugation applications continue to expand, flexible process development capabilities can help accommodate a broader range of product requirements, supporting clients as they advance increasingly complex therapeutic candidates.
Q3. How can manufacturers maintain batch-to-batch consistency in cysteine-based conjugation?
Maintaining consistent product quality is a critical consideration in bioconjugate manufacturing, particularly for conjugation processes that produce a distribution of DAR species. At Samsung Biologics, the approach to demonstrating process consistency evolves according to the development stage.
For early-stage programs, process lock runs are performed to assess the consistency of the established bioconjugation process. The process is then applied to the manufacture of non-GMP drug substance for nonclinical toxicity studies and, following technology transfer, to GMP drug substance.
During scale-up from non-GMP pilot operations to GMP manufacturing, computational fluid dynamics (CFD) modeling is used to support the translation of process conditions across scales. Comparability between non-GMP and GMP drug substance batches is subsequently evaluated through release testing and extended characterization methods. These assessments help demonstrate that material manufactured at different stages maintains comparable quality attributes.
For late-stage clinical and commercial programs, process validation activities, including process performance qualification (PPQ), provide further evidence of manufacturing consistency.
Together, these activities support a systematic approach to maintaining product quality as ADC programs progress from early development toward commercial manufacturing.
Q4. How can contamination control and containment requirements be addressed together in ADC manufacturing?
ADC manufacturing presents a distinct challenge: protecting the product from contamination while simultaneously protecting personnel and the surrounding environment from exposure to highly potent compounds. Although these objectives may appear to require opposing environmental conditions, they can be addressed through an integrated, risk-based contamination control strategy (CCS).
Traditional contamination control focuses on preventing the introduction of microorganisms and particulates into the manufacturing process. Containment, meanwhile, aims to prevent hazardous materials, including highly potent active pharmaceutical ingredients (HPAPIs), from escaping the process boundary.
Samsung Biologics integrates both objectives within its contamination control approach, drawing on quality risk management principles under ICH Q9 and EU GMP Annex 1. During conjugation and payload-handling operations, dedicated isolators operate under negative pressure relative to the surrounding cleanroom, helping prevent hazardous materials from escaping into the working environment. HEPA filtration and closed single-use systems provide additional layers of protection.
For operations conducted within a Grade C cleanroom, pressure differentials are carefully managed to maintain appropriate environmental conditions. While the cleanroom remains positively pressurized relative to adjacent lower-grade areas, the isolator operates under negative pressure relative to the cleanroom.
Sealed transfer interfaces help maintain separation during material movement, while dedicated waste-handling pathways and filtered exhaust systems support the safe management of potentially hazardous residues. Campaign changeovers also require verification of residual payload-linker carryover to manage cross-contamination risks in multiproduct operations. By combining these controls, manufacturers can address product protection and occupational safety within a unified manufacturing framework.
Q5. How can a consistent contamination control strategy support manufacturing across different regulatory policies?
As ADC manufacturing operations expand globally, manufacturers must navigate regulatory expectations across different markets while maintaining consistent approaches to product quality and contamination prevention.
Samsung Biologics uses EU GMP Annex 1 as a foundational framework for its risk-based contamination control strategy across all manufacturing sites. The company introduced its Annex 1-based CCS in 2022, establishing a structured approach covering facility design, utilities, personnel training, raw material controls, cleaning, disinfection, and environmental monitoring. For manufacturing operations in the U.S., this framework is also aligned with applicable FDA current Good Manufacturing Practice (cGMP) requirements, including 21 CFR Parts 210 and 211.
This involves mapping relevant contamination control measures to U.S. regulatory requirements and maintaining supporting documentation, such as validation records, differential pressure monitoring data, operating procedures, and periodic risk assessments.
Rather than treating regional requirements as separate manufacturing approaches, this risk-based framework supports consistency in contamination control practices while allowing facilities to address jurisdiction-specific regulatory expectations.
Supporting the Next Generation of Bioconjugate Therapeutics
As the bioconjugate landscape expands, developers require manufacturing approaches that can accommodate increasingly diverse molecular designs, conjugation technologies, and process requirements.
From selecting appropriate conjugation methods and optimizing process conditions to maintaining manufacturing consistency and implementing risk-based contamination controls, each stage requires specialized technical expertise.
Samsung Biologics brings together bioconjugation process development and manufacturing capabilities to support clients navigating these complexities. Through experience across conjugation technologies, payload types, and development stages, the company continues to expand its ability to address evolving client needs and support the advancement of complex therapeutics.


As bioconjugate therapeutics continue to evolve beyond conventional antibody-drug conjugates (ADCs), developers are exploring increasingly diverse combinations of antibodies, linkers, and functional payloads. These advances are creating new opportunities for targeted therapeutics while introducing additional considerations for process development and manufacturing.
Supporting this growing diversity requires expertise across conjugation technologies, payload characteristics, process optimization, and contamination control. Each component plays an important role in establishing manufacturing processes that can accommodate different molecular properties and development requirements.
During two recent webinars exploring Samsung Biologics' comprehensive bioconjugation services and risk-based contamination control strategies, industry participants raised practical questions about these challenges. In this Q&A article, our two experts will address those questions, sharing insights on technical and operational considerations for ADC development and manufacturing.
Q1. What advantages can enzymatic conjugation offer over conventional conjugation methods?
Selecting the appropriate conjugation technology is a critical step in bioconjugate development, as the method can influence product homogeneity, stability, and overall quality. While conventional cysteine-based conjugation methods are widely used, enzyme-mediated conjugation can offer advantages in controlling drug-to-antibody ratio (DAR) and improving product homogeneity.
One key benefit of enzyme-mediated conjugation is its ability to preserve the antibody's native structure. Unlike certain cysteine-based approaches that involve disrupting native disulfide bonds, enzyme-mediated methods can enable conjugation without altering these structural features. This can contribute to improved ADC stability and more consistent product characteristics.
Greater control over DAR distribution is another important consideration, particularly for ADCs. ADC populations with lower DAR values may exhibit reduced efficacy, while those with higher DAR values can present increased toxicity risks. Achieving a more homogeneous DAR profile can therefore help support a balance between efficacy and safety.
However, no single conjugation approach is optimal for every molecule. Factors such as reaction efficiency, conjugation site specificity, payload characteristics, and desired product attributes must be considered when selecting a suitable method.
Samsung Biologics supports process development and manufacturing across a range of conjugation technologies, including enzyme-mediated approaches, enabling clients to select methods suited to their ADC programs.
Q2. How does experience with different payloads and DAR values support ADC process development?
The increasing diversity of bioconjugate modalities introduces a wide range of molecular characteristics and process requirements. Different payloads and linker combinations can influence conjugation efficiency, product stability, and manufacturing conditions. For ADC development in particular, experience handling highly potent payloads and achieving different DAR targets is essential to establishing suitable conjugation processes.
Samsung Biologics has experience handling and conjugating a variety of payloads, including monomethyl auristatin E (MMAE)*, exatecan*, pyrrolobenzodiazepine* (PBD), and oligonucleotides*. Its process development experience also encompasses target DAR values ranging from 1 to 8. This experience provides a foundation for evaluating different payload-linker combinations and developing conjugation processes tailored to specific product requirements.
* Monomethyl auristatin E (MMAE) is a potent synthetic antimitotic agent derived from the marine-derived peptide dolastatin 10.
* Exatecan (DX-8951) is a potent, water-soluble structural analog of camptothecin and a DNA topoisomerase I inhibitor.
* Pyrrolobenzodiazepine (PBD) is a highly potent ADC payload that kills cancer cells by damaging their DNA.
* Oligonucleotide conjugation is the process of chemically linking short DNA or RNA molecules to other molecules, such as antibodies, peptides, or lipids, to improve targeted drug delivery and therapeutic effectiveness.
As bioconjugation applications continue to expand, flexible process development capabilities can help accommodate a broader range of product requirements, supporting clients as they advance increasingly complex therapeutic candidates.
Q3. How can manufacturers maintain batch-to-batch consistency in cysteine-based conjugation?
Maintaining consistent product quality is a critical consideration in bioconjugate manufacturing, particularly for conjugation processes that produce a distribution of DAR species. At Samsung Biologics, the approach to demonstrating process consistency evolves according to the development stage.
For early-stage programs, process lock runs are performed to assess the consistency of the established bioconjugation process. The process is then applied to the manufacture of non-GMP drug substance for nonclinical toxicity studies and, following technology transfer, to GMP drug substance.
During scale-up from non-GMP pilot operations to GMP manufacturing, computational fluid dynamics (CFD) modeling is used to support the translation of process conditions across scales. Comparability between non-GMP and GMP drug substance batches is subsequently evaluated through release testing and extended characterization methods. These assessments help demonstrate that material manufactured at different stages maintains comparable quality attributes.
For late-stage clinical and commercial programs, process validation activities, including process performance qualification (PPQ), provide further evidence of manufacturing consistency.
Together, these activities support a systematic approach to maintaining product quality as ADC programs progress from early development toward commercial manufacturing.
Q4. How can contamination control and containment requirements be addressed together in ADC manufacturing?
ADC manufacturing presents a distinct challenge: protecting the product from contamination while simultaneously protecting personnel and the surrounding environment from exposure to highly potent compounds. Although these objectives may appear to require opposing environmental conditions, they can be addressed through an integrated, risk-based contamination control strategy (CCS).
Traditional contamination control focuses on preventing the introduction of microorganisms and particulates into the manufacturing process. Containment, meanwhile, aims to prevent hazardous materials, including highly potent active pharmaceutical ingredients (HPAPIs), from escaping the process boundary.
Samsung Biologics integrates both objectives within its contamination control approach, drawing on quality risk management principles under ICH Q9 and EU GMP Annex 1. During conjugation and payload-handling operations, dedicated isolators operate under negative pressure relative to the surrounding cleanroom, helping prevent hazardous materials from escaping into the working environment. HEPA filtration and closed single-use systems provide additional layers of protection.
For operations conducted within a Grade C cleanroom, pressure differentials are carefully managed to maintain appropriate environmental conditions. While the cleanroom remains positively pressurized relative to adjacent lower-grade areas, the isolator operates under negative pressure relative to the cleanroom.
Sealed transfer interfaces help maintain separation during material movement, while dedicated waste-handling pathways and filtered exhaust systems support the safe management of potentially hazardous residues. Campaign changeovers also require verification of residual payload-linker carryover to manage cross-contamination risks in multiproduct operations. By combining these controls, manufacturers can address product protection and occupational safety within a unified manufacturing framework.
Q5. How can a consistent contamination control strategy support manufacturing across different regulatory policies?
As ADC manufacturing operations expand globally, manufacturers must navigate regulatory expectations across different markets while maintaining consistent approaches to product quality and contamination prevention.
Samsung Biologics uses EU GMP Annex 1 as a foundational framework for its risk-based contamination control strategy across all manufacturing sites. The company introduced its Annex 1-based CCS in 2022, establishing a structured approach covering facility design, utilities, personnel training, raw material controls, cleaning, disinfection, and environmental monitoring. For manufacturing operations in the U.S., this framework is also aligned with applicable FDA current Good Manufacturing Practice (cGMP) requirements, including 21 CFR Parts 210 and 211.
This involves mapping relevant contamination control measures to U.S. regulatory requirements and maintaining supporting documentation, such as validation records, differential pressure monitoring data, operating procedures, and periodic risk assessments.
Rather than treating regional requirements as separate manufacturing approaches, this risk-based framework supports consistency in contamination control practices while allowing facilities to address jurisdiction-specific regulatory expectations.
Supporting the Next Generation of Bioconjugate Therapeutics
As the bioconjugate landscape expands, developers require manufacturing approaches that can accommodate increasingly diverse molecular designs, conjugation technologies, and process requirements.
From selecting appropriate conjugation methods and optimizing process conditions to maintaining manufacturing consistency and implementing risk-based contamination controls, each stage requires specialized technical expertise.
Samsung Biologics brings together bioconjugation process development and manufacturing capabilities to support clients navigating these complexities. Through experience across conjugation technologies, payload types, and development stages, the company continues to expand its ability to address evolving client needs and support the advancement of complex therapeutics.
Share article
Related Content



